Get the Stockscreener App
488.26
2.23%
10.66
After Hours:
489.00
0.74
+0.15%
Madrigal Pharmaceuticals Inc stock is traded at $488.26, with a volume of 397.91K.
It is up +2.23% in the last 24 hours and down -5.02% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$477.60
Open:
$477.6
24h Volume:
397.91K
Relative Volume:
1.14
Market Cap:
$11.09B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-19.44
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-0.30%
1M Performance:
-5.02%
6M Performance:
+41.23%
1Y Performance:
+46.75%
1-Day Range:
$471.39
$490.50
1-Week Range:
$458.00
$491.29
52-Week Range:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
488.26 | 10.85B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal Grants Equity to New Hires as MASH Drug Momentum Builds - MyChesCo
Madrigal Sets Date to Reveal 2025 Results as Investors Watch Closely - MyChesCo
Aug Update: Is Madrigal Pharmaceuticals Inc stock good for income investorsRate Hike & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule - marketscreener.com
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule - TradingView
21 new Madrigal hires receive 5,861 stock units vesting over 4 years - stocktitan.net
Commit To Buy Madrigal Pharmaceuticals At $350, Earn 14.6% Annualized Using Options - Nasdaq
Does Madrigal Pharmaceuticals (MDGL) Offer Value After Recent Share Price Weakness - simplywall.st
Madrigal Pharmaceuticals stock maintains Buy rating at B.Riley on strong Rezdiffra growth - Investing.com Canada
Madrigal Pharmaceuticals to report financial results on February 19 - Traders Union
18,291 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by WCM Investment Management LLC - MarketBeat
How (MDGL) Movements Inform Risk Allocation Models - Stock Traders Daily
Novo Set To Make MASH Move On Madrigal In EU With Kayshild - Citeline News & Insights
Madrigal Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Quiver Quantitative
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026 - The Manila Times
Madrigal Pharmaceuticals to Release Fourth-Quarter and - GlobeNewswire
Madrigal Pharmaceuticals (MDGL) Price Target Increased by 10.39% to 562.78 - MSN
Pharma News: How does INNV perform in inflationary periods2025 Trading Recap & Weekly Stock Performance Updates - baoquankhu1.vn
Valuation Update: Will Madrigal Pharmaceuticals Inc outperform during market rallies2025 Performance Recap & Fast Moving Market Watchlists - baoquankhu1.vn
Breakouts Watch: What are analysts price targets for Madrigal Pharmaceuticals IncCEO Change & Technical Entry and Exit Alerts - baoquankhu1.vn
Bull Bear: Is Madrigal Pharmaceuticals Inc stock a value trapIndex Update & Precise Swing Trade Entry Alerts - baoquankhu1.vn
New York State Common Retirement Fund Grows Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Gains Expanded Patent Control Over Rezdiffra With Roche - TipRanks
Madrigal Pharmaceuticals Signs Amendment to Research and Commercialization Agreement With Roche - TradingView
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Madrigal Weighs Pfizer MASH License And Insider Selling In Growth Plan - Sahm
Is Madrigal Pharmaceuticals Inc. stock a value trapTrade Entry Report & Technical Entry and Exit Alerts - mfd.ru
Madrigal Pharmaceuticals (NASDAQ:MDGL) Now Covered by Barclays - MarketBeat
J. Safra Sarasin Holding AG Sells 4,426 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Rezdiffra Sales Milestone and Pfizer DGAT-2 Deal Might Change The Case For Investing In Madrigal Pharmaceuticals (MDGL) - Sahm
Nonalcoholic Steatohepatitis Market to Evolve Rapidly Over the Next Decade, DelveInsight Observes | Madrigal Pharmaceuticals, Novo Nordisk, 89bio - Barchart.com
Madrigal Grants Equity to 40 New Hires as MASH Drug Push Accelerates - MyChesCo
Can Madrigal Pharmaceuticals Inc. stock double in the next yearQuarterly Trade Summary & AI Driven Stock Movement Reports - mfd.ru
MDGL: Barclays Initiates Coverage with Overweight Rating | MDGL Stock News - GuruFocus
Madrigal Taps New Accounting Chief With Six-Figure Equity Bet - mychesco.com
Is Madrigal Pharmaceuticals (MDGL) Still Attractively Priced After Recent Share Price Pullback? - Yahoo Finance
Madrigal Pharmaceuticals Lobbying And Insider Sales Put Valuation In Focus - Sahm
EFG Asset Management North America Corp. Acquires New Shares in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Taub, Madrigal Pharmaceuticals director, sells $318k in shares By Investing.com - Investing.com Canada
Carole Huntsman Sells 910 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO Sells 1,577 Shares of Stock - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Rebecca Taub Sells 647 Shares - MarketBeat
Huntsman, chief commercial officer, sells $449k in Madrigal (MDGL) By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Madrigal Pharmaceuticals Grants Equity Awards to New Hires Under Inducement Plan - MSN
Fundamentals Check: Will AMZE outperform during market ralliesQuarterly Trade Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Volume Recap: Will Madrigal Pharmaceuticals Inc benefit from seasonalityJuly 2025 Setups & Long-Term Capital Growth Strategies - baoquankhu1.vn
Trading Systems Reacting to (MDGL) Volatility - Stock Traders Daily
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Down 5.1%Here's Why - MarketBeat
Relative Strength Alert For Madrigal Pharmaceuticals - Nasdaq
Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Madrigal Pharmaceuticals Inc Stock (MDGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Huntsman Carole | Chief Commercial Officer |
Jan 26 '26 |
Sale |
493.78 |
910 |
449,339 |
9,122 |
0.10%
7.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):